The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03181191

Enrollment

Registered

2017-06-08

Start date

2017-04-27

Completion date

2017-12-03

Last updated

2019-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucose Metabolism Disorders

Brief summary

Delineation of the anatomical location, cellular origin and molecular basis of gut-derived glucagon secretion

Detailed description

Aim: to delineate the anatomical origin, the molecular structure and precursors, the regulation and the (patho-) physiological implications of gut-derived glucagon. Eight totally pancreatectomised patients, eight type 2 diabetes patients and eight healthy controls (age 18-80, BMI \<30) with normal kidney and liver parameters and hgb\> 6.5 - will be included. The participants will each undergo one screening day and one study day including a gastroduodenoscopy. Multiple biopsies will be taken at several predefined locations in the upper gastrointestinal tract. These biopsies will be analysed with different techniques including immunohistochemical staining, quantitative polymerase chain reaction (qPCR-) analyses and more to search for glucagon. After the last biopsy has been collected, 50 g of glucose dissolved in 100 ml water is infused through the enteroscope into the most proximal part of the small intestine. Hereafter blood samples for glucagon and gut hormone analyses will be collected 15, 30 and 45 min after the glucose infusion.

Interventions

OTHEROral glucose tolerance test

Oral glucose tolerance test and biopsies

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* normal kidney function, normal liver function, normal hemoglobin levels

Exclusion criteria

* diabetes type 1, first degree relatives with type 2 diabetes

Design outcomes

Primary

Measure	Time frame	Description
gut-derived glucagon	1 year	The primary objective is to investigate mucosal biopsies from specific regions of the upper gastrointestinal tract

Secondary

Measure	Time frame	Description
Oral glucose tolerance test	45 minutes	Glucose metabolism - hormones, insulin, glucagon, glp-1

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026